Other Events ·
HUTCHMED (China) Limited announced that clinical data for its oncology portfolio will be presented at the ESMO…
HMDCFHUTCHMED (China) Ltd
HUTCHMED (China) Limited announced that clinical data for its oncology portfolio will be presented at the ESMO Congress 2026 in Madrid. The company highlighted late-breaking abstracts from two positive Phase III studies of the savolitinib and osimertinib combination for non-small cell lung cancer, including the global SAFFRON study and the China-based SANOVO study. Additional data on fruquintinib, surufatinib, and other combinations will be presented in poster sessions and symposia throughout October 2026. HUTCHMED is a biopharmaceutical company focused on the discovery and commercialization of targeted cancer therapies.